Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial

Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial

ObjectivesCanagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated, and it could become a novel option in the PCOS treatment. Nevertheless, trials focused on SGLT-2 combin...

Full description

Bibliographic Details
Main Authors: Jiaqi Zhang, Chuan Xing, Xiangyi Cheng, Bing He
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Endocrinology
Subjects:
sodium-glucose co-transporter 2 inhibitors
canagliflozin
metformin
weight-loss
polycystic ovary syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.1003238/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.1003238/full

Similar Items